On October 31, 2022 Zhuhai Beihai Biotech reported that it raised $27 million in a Series B Round to develop novel oncology drugs (Press release, Zhuhai Beihai Biotech, OCT 31, 2022, View Source [SID1234622624]). Founded in 2013, Beihai’s lead drug, an innovative docetaxel product, has completed its clinical trials with seven IND approvals in China and the US. The company claims BH009 is the first global candidate built on its insoluble drug solubilization and delivery technology platform. A broad-spectrum antitumor drug, BH009 is indicated for solid tumors. The B round was led by Yikai Venture Capital

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!